Home » Stocks » ADPT

Adaptive Biotechnologies Corporation (ADPT)

Stock Price: $34.99 USD -1.61 (-4.40%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $35.34 +0.35 (1.00%) May 7, 7:04 PM
Market Cap 4.91B
Revenue (ttm) 115.91M
Net Income (ttm) -155.47M
Shares Out 138.97M
EPS (ttm) -1.16
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $34.99
Previous Close $36.60
Change ($) -1.61
Change (%) -4.40%
Day's Open 36.53
Day's Range 34.86 - 37.51
Day's Volume 1,747,590
52-Week Range 33.53 - 71.25

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 29.27% and 34.73%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 days ago - Zacks Investment Research

SEATTLE, May 05, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics o...

4 days ago - GlobeNewsWire

Adaptive Biotechnologies (NASDAQ:ADPT) announces its next round of earnings this Wednesday, May 05. Here is Benzinga's everything-that-matters guide for this Wednesday's Q1 earnings announcement.

5 days ago - Benzinga

Adaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

SEATTLE, April 27, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system...

1 week ago - GlobeNewsWire

Viking Global leader Andreas Holversen disclosed a stake in Mudrick Capital Acquistion Corp. II (NASDAQ:MUDS) earlier this month, seeing yet another value opportunity in special purpose acquisition comp...

Other stocks mentioned: BBIO, DIS, FIS, MSFT, MUDS, TMUS
2 weeks ago - GuruFocus

Meridian Bioscience Inc. (NASDAQ:VIVO) edged out GenMark Diagnostics Inc. (NASDAQ:GNMK) as the top gainer in the March GenomeWeb Index with a 25% boost in its share price compared to GenMark's 22.5% inc...

Other stocks mentioned: BRN, GNMK, RHHBY, VIVO
3 weeks ago - GuruFocus

We're really excited that these genomics companies, says Ark's Simon Barnett

YouTube video

Simon Barnett, ARK Invest's genomics analyst, discusses the company's belief in Invitae, its other top picks and why ARK invests the way it does.

Other stocks mentioned: ARKG, NVTA, PACB
3 weeks ago - CNBC Television

SEATTLE, April 12, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT)  a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syste...

3 weeks ago - GlobeNewsWire

Viking Global leader Andreas Holversen disclosed a stake in Orion Acquisition Corp. (NASDAQ:OHPAU) earlier this month, joining a growing number of investors who are seeing value opportunities in special...

Other stocks mentioned: BBIO, FIS, MSFT, TMUS
1 month ago - GuruFocus

SEATTLE, March 17, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune syste...

1 month ago - GlobeNewsWire

The confluence of healthcare and technology will send many biotech stocks soaring over the next decade.

Other stocks mentioned: AMGN, BNTX, ILMN, MRNA, MSFT
1 month ago - The Motley Fool

Adaptive Biotech T cell test receives FDA approval for emergency use

YouTube video

Adaptive Biotech's T cell test will help detect whether you've had Covid-19 before or not. The test just received FDA approval for emergency use.

2 months ago - CNBC Television

The shares of Adaptive Biotechnologies Corp (NASDAQ:ADPT) are sinking even lower today, following a price-target cut to $60 from $68 from Guggenheim.

2 months ago - Schaeffers Research

The FDA issued the Emergency Use Authorization (EUA) to Adaptive Biotechnologies Corp's (NASDAQ: ADPT) T-Detect COVID-19 Test on Friday. It will be used to determine whether an individual had been infec...

2 months ago - Benzinga

First and only clinical T cell-based test for patients to detect the unique T-cell signature specific to SARS-CoV-2, the virus that causes COVID-19

2 months ago - GlobeNewsWire

With the trading day about halfway over, the broad markets have not made up their minds on a direction for the day.

Other stocks mentioned: MSFT, ORCL, SPCE, TSLA, CTXS, DHR, DOCU ...
2 months ago - 24/7 Wall Street

2020 was a year that will be hard to forget. The headlines were dominated by the pandemic and its social and economic aftermath, but there were also wildfires, violent social and racial unrest, the U.S....

Other stocks mentioned: OZON, SNOW, TSLA, TXG, ZI
2 months ago - GuruFocus

SEATTLE, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system ...

2 months ago - GlobeNewsWire

Seattle-based Adaptive Biotechnologies, which sequences the human immune system to diagnose and treat disease, posted revenue of $30.

2 months ago - GeekWire

Shares of Adaptive Biotechnologies (NASDAQ:ADPT) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 94.12% year over year to ($0.33), whic...

2 months ago - Benzinga

SEATTLE, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics ...

2 months ago - GlobeNewsWire

Adaptive Biotechnologies Corp (NASDAQ: ADPT) launched a clinical T-cell-based test kit to confirm recent or prior COVID-19 infection.  T-Detect is currently under review by the FDA for Emergency Use Aut...

2 months ago - Benzinga

SEATTLE, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system...

2 months ago - GlobeNewsWire

T-Detect is currently under review by the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA)

2 months ago - GlobeNewsWire

Julian Robertson (Trades, Portfolio)'s Tiger Management recently disclosed its portfolio updates for the fourth quarter of 2020, which ended on Dec. 31.

Other stocks mentioned: AER, BKNG, CRM, FB, SYF, VNET
2 months ago - GuruFocus

Adaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

SEATTLE, Feb. 02, 2021 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT)  a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system...

3 months ago - GlobeNewsWire

Multi-year, pan-portfolio deal extends Adaptive's proprietary immunoSEQ T-MAP offering, originally launched for COVID-19, into oncology

3 months ago - GlobeNewsWire

During GuruFocus' annual model portfolio rebalance for 2021, the new stocks added to the Most Weighted Model Portfolio were Adaptive Biotechnologies Corp. (NASDAQ:ADPT), AerCap Holdings NV (NYSE:AER), A...

Other stocks mentioned: AER, BABA, DIS, PCG, TRN
4 months ago - GuruFocus

SEATTLE, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics ...

4 months ago - GlobeNewsWire

Investors need to pay close attention to Adaptive Biotechnologies (ADPT) stock based on the movements in the options market lately.

4 months ago - Zacks Investment Research

According to current portfolio statistics, a Premium feature of GuruFocus, the top five health care positions in Andreas Halvorsen (Trades, Portfolio)'s equity portfolio as of the third quarter are Adap...

Other stocks mentioned: BBIO, BSX, CNC, TMO
4 months ago - GuruFocus

MRD assessment with clonoSEQ improves outcomes both for patients and the healthcare system, as patients with undetectable MRD may be able to discontinue active treatment MRD assessment with clonoSEQ imp...

5 months ago - GlobeNewsWire

SEATTLE, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system...

5 months ago - GlobeNewsWire

Andreas Halvorsen (Trades, Portfolio), a founding partner of Viking Global, disclosed this week that his firm's top sells during the third quarter were in Amazon.com Inc. (NASDAQ:AMZN), Comcast Corp. (N...

Other stocks mentioned: AMZN, CMCSA, JD, UBER
5 months ago - GuruFocus

Investors are hyper-focused on COVID-19 right now, but once vaccines for the virus have been approved, other healthcare stocks will start to zoom forward.

Other stocks mentioned: BLUE, BPMC, NVAX, RHHBY
5 months ago - The Motley Fool

Adaptive Biotechnologies says it's proceeding with plans to launch a new type of test to determine if someone was previously infected with SARS-CoV-2, the virus that causes COVID-19, after a study added...

5 months ago - GeekWire

– Findings support upcoming launch of T-Detect ™ COVID , first T- cell test for novel coronavirus – Data support mounting evidence that measuring T- cell s is necessary to fully characteriz e immune res...

5 months ago - GlobeNewsWire

Adaptive Biotechnologies' (ADPT) CEO Chad Robins on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Adaptive Biotechnologies beat expectations for its fiscal third quarter as the Seattle company continues to use its immune medicine platform in the fight against COVID-19.

Other stocks mentioned: GSK
5 months ago - GeekWire

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of 3.57% and 12.26%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Shares of Adaptive Biotechnologies (NASDAQ:ADPT) were flat in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share fell 145.45% over the past year to ($0.27),...

5 months ago - Benzinga

SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system...

5 months ago - GlobeNewsWire

SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics ...

5 months ago - GlobeNewsWire

Adaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

Adaptive Biotech CEO says it's working to develop the best antibody treatment for Covid-19

YouTube video

Adaptive biotechnologies CEO Chad Robins says the company is working night and day to develop an effective antibody Covid-19 treatment. He says the company won't be first to provide antibody treatments,...

6 months ago - CNBC Television

SEATTLE, Oct. 13, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT) a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system ...

6 months ago - GlobeNewsWire

SEATTLE, Sept. 01, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune sys...

8 months ago - GlobeNewsWire

Adaptive Biotechnologies: T-Cell Explorer In COVID-19 Battle Deserves A Premium

8 months ago - Seeking Alpha

About ADPT

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease i... [Read more...]

Industry
Biotechnology
IPO Date
Jun 27, 2019
CEO
Chad Robins
Employees
622
Stock Exchange
NASDAQ
Ticker Symbol
ADPT
Full Company Profile

Financial Performance

In 2020, ADPT's revenue was $98.38 million, an increase of 15.65% compared to the previous year's $85.07 million. Losses were -$146.23 million, 113.1% more than in 2019.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for ADPT stock is "Buy." The 12-month stock price forecast is 62.00, which is an increase of 77.19% from the latest price.

Price Target
$62.00
(77.19% upside)
Analyst Consensus: Buy